CCL2 and metabolic dysfunction-associated steatohepatitis: The current work showed that blocking the bioactivity of CCN2 decreased MCP-1 gene expression and it improved TNF-α levels in the HFD + DM NASH model, suggesting that CCN2 is pro-inflammatory in this model.